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Over the last few decades, there has been 
a steady increase in the number and 
percentage of women in medicine. The 
number of women enrolling at medical 
schools currently exceeds that of men in 
many US and European Universities. In the 
oncology field, the change is reflected in the 
year- on- year growth in female membership of 
the European Society for Medical Oncology 
(ESMO). In 2000, women made up just 20% 
of ESMO members. Now, almost half of all 
ESMO members are women, including 54% 
of members under 40.
However, female representation in 
decision- making positions remains low. 
Female physicians continue to face myriad 
challenges in medicine ranging from implicit 
bias to barriers to promotion, responsibility 
and gaps in payment. Consequently, although 
an equal number of men and women now 
graduates from medical school, only a small 
fraction of female physicians become medical 
leaders. In academic medicine, women make 
up only 42% of all US medical school faculty, 
24% of full professors, 17% of department or 
division chairs and 16% of deans.1 Women 
are also vastly under- represented in author, 
reviewer and editorial position across scien-
tific and medical journals.2 Finally, there is 
also a well- documented gender disparity in 
the scientist- focused funding programme, 
start- up packages and grant application 
review processes.3–5 Gender bias is sometimes 
unconscious6 but even the use of a different 
level of formality when introducing a female 
or a male speaker may influence how people 
perceive expertise and competency.7
Through the Women for Oncology (W4O) 
Committee, ESMO aims to promote equal 
access to career development opportuni-
ties for female oncologists and to support 
them by monitoring and raising awareness 
about gender imbalance. An ESMO research 
conducted on data from 2015 to 2016 high-
lighted that less than half of female cancer 
specialists had a leadership role compared 
with two- thirds of their male colleagues. 
Only 1 in 4 board members of international 
oncology societies was woman and just 1 in 
10 of these societies had a female president.8 
A few years later, through the W4O moni-
toring study, we can say that women are still 
confined to under a third of seats on top 
decision- making committees.
W4O also published a survey on gender- 
related challenges in oncology. For the 
majority of respondents (women 54.6% and 
men 43.2%), the main barrier that prevents 
reaching gender parity in the oncology 
field is the lack of work–life balance. Men 
perceived as natural leaders and cultural prej-
udice about priority in family and domestics 
responsibilities were also cited as reasons for 
gender gap.9
In recognition of the importance of gender 
balance in all areas of health and medicine, 
ESMO keeps committed to diversity through 
different initiatives, including providing 
resources and support access to training 
and career development opportunities. 
Gender equality remains frustratingly elusive. 
Numerous causes have been suggested, but 
one argument that persists points to differ-
ences in men and women’s behaviour and 
roles and subsequently their societal recogni-
tion. Acknowledging existing differences and 
dismantling gender stereotypes are the first 
steps in looking for long- term solutions.
Some variables such as family, education, 
mentoring and role models can be especially 
challenging for women and influenced by 
local barriers. Having first- hand information 
about potential differences based on cultural 
or social pressure is key to understand why 
gender bias emerged and how it is perceived.
Aiming to identify local needs in the 
gender equity field, a series of surveys have 
been recently proposed by the ESMO W4O 
Committee to be published under the name 
‘W4O in…’. These papers will be focused 
on differences and/or similarities in how 
national societies and regional organisa-
tions face gender gap and what are the local 
aspects strategically key for success. Given the 
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value placed on data and evidence in cancer care and 
medicine in general, the impact of these interventions 
will be further increased by rigorous study of their effects. 
In the meantime, they provide valuable starting points for 
a problem affecting not just female physicians, but the 
health and performance of the systems they work in. This 
information will help ESMO to design, in a more effective 
way, future activities to motivate and to promote female 
oncologists’ aspirations and leadership.
The paper entitled ‘Gender climate in Indian oncology: 
national survey report’ is intended to be the first of this 
series. Bajpai et al10 launched an exploratory survey on the 
challenges of female oncologists in India. The aim of the 
study was to identify cultural obstacles and gender taboos 
faced by women professionals leading to a significant 
gender bias in the medical field. Most of the questions 
mirrored the 2016 ESMO W4O survey on gender- related 
challenges that included opinions from professionals 
working mainly in Europe (71.7%). In both of them, at 
least two- third of responding were women (61% in Indian 
survey, 76.7% in ESMO) and aged under 45 (69.4% and 
67%, respectively). Having a woman as responsible for 
the team occurred in a very similar percentage of cases in 
both surveys (32.7% and 35.3%). In terms of challenges, 
the greatest barrier to career advancement for women 
oncologist was the balance between work and family in 
both of them. This concern was also identified in a survey 
conducted in Italy11 among young oncologists (201 
participants, 67% women). Considering that 29% aged 
under 30 and 82% of them did not have children, the fact 
of facing similar barriers across regions, cultural and age 
differences deserves further analysis.
Academic advancement often depends on publica-
tions and reflects leadership within a profession. Several 
studies evaluating the proportion of women first and 
senior authorship over time highlighted the existing 
gender gap also in this field. In the series from India, 
Bajpai et al showed that only 26% of articles published 
in two leading oncology journals in India in 2017–2018 
had a female lead author. This percentage is not far from 
a recent paper conducting a bibliometric analysis of five 
prominent oncology journals. Dalal et al12 demonstrated 
that, despite positive trends, there is still a persistent 
substantial gendered difference in oncology publica-
tions including 36.6% of first author and 28.5% of senior 
authors in 2017.
Diversity in human capital and resources can bring 
diversity in thought, leading to innovation, stronger teams 
and better outcomes for patients. Traditional concep-
tions of gender roles might partially shape the disparities 
experienced by women pursuing medical careers in each 
region of the world, and they need to be acknowledged 
and addressed. While gender gap seems to be slowly 
narrowing, there is still a clear room for improvement in 
many areas. Some of them are to increase the visibility 
of women, to facilitate sponsorships, mentorships and 
training programmes and to contribute to the awareness 
and correction of this inequity. New generations deserve 
our efforts and ESMO will be there for them.
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